N/A
Completed N=64
Cortical Contributions to Motor Sequence Learning
Brain Injuries
Source: ClinicalTrials.gov NCT04138953 ↗
Enrolled (actual)
64
Serious AEs
0.0%
Results posted
Aug 2024
Primary outcomePrimary: Serial Reaction Time Task (SRTT) Performance — 31; 35; 38; 24 milliseconds (ms)
Summary
The long-term objective initiated with this study is to determine which brain areas functionally contribute to learning a motor skill. The primary hypothesis of this trial is that premotor cortex (PMC) is necessary to learn a new motor skill. Participants may undergo a MRI scan to acquire a structural image of their brain to target noninvasive stimulation, using transcranial magnetic stimulation (TMS) to one of two brain areas: PMC or primary motor cortex (M1). A third group of individuals will undergo a placebo stimulation protocol. For all three groups, stimulation will be used to create a transient 'virtual lesion' during motor skill training. Temporarily disrupting the normal activity of these brain regions during training will allow us to determine which regions are causally involved in learning a new motor skill. The primary outcome measure will be the change in skill after training in each group.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Serial Reaction Time Task (SRTT) Performance |
31; 35; 38; 24; 30; 17 | — |
| SECONDARY Cortical Excitability Measured by Motor Evoked Potentials (MEPs) |
1.03; 1.29; 0.45; 1.15; 1.37; 0.51 | — |
Eligibility Criteria
Inclusion Criteria
- No history of movement impairment or neurodegenerative disease
- Right handedness
- No contraindication to transcranial magnetic stimulation (TMS) or magnetic resonance imaging (MRI).
Exclusion Criteria
- Participants that are outside the age range of 18-85
- Have a history of head trauma or neurodegenerative disorder
- Report contraindications to TMS.
- Participants over age 65 will be asked to complete the Montreal Cognitive Assessment, and participants with a score of 25 or lower (out of the "normal" range) will be excluded.
Data sourced from ClinicalTrials.gov (NCT04138953). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.